Ascendis Pharma A/S (ASND)

137.20 -3.90 (-2.76%) 收市：04:00PM EDT

Ascendis Pharma A/S

Tuborg Boulevard 12
Hellerup 2900
Denmark
45 70 22 22 44
https://ascendispharma.com

版塊: Healthcare
行業: Biotechnology
全職員工: 879

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Jan Moller Mikkelsen	President, CEO, Member of Executive Board & Executive Director	無	無	1960
Mr. Scott T. Smith	CFO, Executive VP & Member of Executive Board	無	無	1974
Ms. Lotte Sonderbjerg	Executive VP, Chief Administrative Officer & Member of the Executive Board	無	無	1961
Mr. Michael Wolff Jensen L.L.M.	Executive VP, Chief Legal Officer & Member of the Executive Board	無	無	1971
Mr. Mads Bodenhoff	Senior VP of Finance & Principal Accounting Officer	無	無	無
Mr. Timothy J. Lee	Senior Director of Investor Relations	無	無	無
Mr. Flemming Steen Jensen	Executive Vice President of Product Supply & Quality	無	無	1961
Dr. Kennett Sprogoe Ph.D.	Executive VP and Head of Research & Product Development	無	無	1979
Dr. Stina Singel M.D., Ph.D.	Executive VP & Head of Clinical Development for Oncology	無	無	1974
Mr. Joseph Kelly	Head of U.S. Commercial of Endocrinology	無	無	1969

截止 2022年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

公司管治

截至 無 止，Ascendis Pharma A/S 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。